{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:50:33Z","timestamp":1786794633918,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40263-019-00694-4","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:02:46Z","timestamp":1576504966000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-0907","authenticated-orcid":false,"given":"David S.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo J. F.","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"2","key":"694_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0022-3476(80)80517-8","volume":"97","author":"B Dalens","year":"1980","unstructured":"Dalens B, Raynaud E-J, Gaulme J. Teratogenicity of valproic acid. J Pediatr. 1980;97(2):332\u20133.","journal-title":"J Pediatr"},{"issue":"3","key":"694_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ajmg.1320190308","volume":"19","author":"JH Di Liberti","year":"1984","unstructured":"Di Liberti JH, et al. The fetal valproate syndrome. Am J Med Genet. 1984;19(3):473\u201381.","journal-title":"Am J Med Genet"},{"issue":"23","key":"694_CR3","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","volume":"362","author":"J Jentink","year":"2010","unstructured":"Jentink J, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185\u201393.","journal-title":"N Engl J Med"},{"key":"694_CR4","first-page":"10236","volume":"10","author":"R Bromley","year":"2014","unstructured":"Bromley R, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10:10236.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"694_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.yebeh.2013.08.001","volume":"29","author":"MJ Cohen","year":"2013","unstructured":"Cohen MJ, et al. Fetal antiepileptic drug exposure: adaptive and emotional\/behavioral functioning at age 6 years. Epilepsy Behav. 2013;29(2):308\u201315.","journal-title":"Epilepsy Behav"},{"issue":"16","key":"694_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696\u2013703.","journal-title":"JAMA"},{"issue":"2","key":"694_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15(2):210\u20138.","journal-title":"Lancet Neurol"},{"issue":"3","key":"694_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1192\/bjp.2019.137","volume":"215","author":"DC Owens","year":"2019","unstructured":"Owens DC. Sodium valproate in psychiatric practice: time for a change in perception. Br J Psychiatry. 2019;215(3):516\u20138.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"694_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","volume":"81","author":"K Meador","year":"2008","unstructured":"Meador K, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1\u201313.","journal-title":"Epilepsy Res"},{"issue":"1","key":"694_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.yebeh.2008.01.010","volume":"13","author":"SV Thomas","year":"2008","unstructured":"Thomas SV, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008;13(1):229\u201336.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"694_CR11","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/j.1528-1167.2010.02668.x","volume":"51","author":"RL Bromley","year":"2010","unstructured":"Bromley RL, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51(10):2058\u201365.","journal-title":"Epilepsia"},{"issue":"16","key":"694_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","volume":"360","author":"KJ Meador","year":"2009","unstructured":"Meador KJ, et al. Cognitive function at 3\u00a0years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360(16):1597\u2013605.","journal-title":"N Engl J Med"},{"issue":"3","key":"694_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6\u00a0years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244\u201352.","journal-title":"Lancet Neurol"},{"issue":"5","key":"694_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/0269881117699361","volume":"31","author":"RH McAllister-Williams","year":"2017","unstructured":"McAllister-Williams RH, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519\u201352.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"694_CR15","doi-asserted-by":"publisher","first-page":"e020450","DOI":"10.1136\/bmjopen-2017-020450","volume":"8","author":"C Paton","year":"2018","unstructured":"Paton C, et al. A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. BMJ Open. 2018;8(4):e020450.","journal-title":"BMJ Open"},{"key":"694_CR16","unstructured":"US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. 2018."},{"issue":"12","key":"694_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0004867415617657","volume":"49","author":"GS Malhi","year":"2015","unstructured":"Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087\u2013206.","journal-title":"Aust N Z J Psychiatry"},{"key":"694_CR18","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacological treatments in patients with epilepsy: guidelines. CADTH; 2011."},{"key":"694_CR19","volume-title":"Best practice guidelines for mental health disorders in the perinatal period","author":"BC Reproductive Mental Health Program","year":"2014","unstructured":"BC Reproductive Mental Health Program. Best practice guidelines for mental health disorders in the perinatal period. Vancouver: BC Mental Health and Substance Use Services and Perinatal Services; 2014."},{"key":"694_CR20","volume-title":"New measures to avoid valproate exposure in pregnancy endorsed","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. London: EMA; 2018."},{"key":"694_CR21","unstructured":"MHRA. Valproate use by women and girls. 2018; updated June 2019. Available from: https:\/\/www.gov.uk\/guidance\/valproate-use-by-women-and-girls. Accessed 08 Dec 2019."},{"key":"694_CR22","volume-title":"Withdrawal of, and alternatives to, valproate-containing medicines in girls and women of childbearing potential who have a psychiatric illness, in Position Statement","author":"D Baldwin","year":"2018","unstructured":"Baldwin D, Wieck A. Withdrawal of, and alternatives to, valproate-containing medicines in girls and women of childbearing potential who have a psychiatric illness, in Position Statement. London: Royal College of Psychiatrists; 2018."},{"issue":"5","key":"694_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/17425250902911455","volume":"5","author":"PM Haddad","year":"2009","unstructured":"Haddad PM, et al. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol. 2009;5(5):539\u201351.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"694_CR24","first-page":"193","volume":"28","author":"Q-Y Song","year":"2013","unstructured":"Song Q-Y, Guo L-T. Trends in the prescribing of psychotropic medications for inpatient children and adolescents, 2000\u20132010: a study from China. Int Clin Psychopharmacol. 2013;28(4):193\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"694_CR25","doi-asserted-by":"publisher","first-page":"e92573","DOI":"10.1371\/journal.pone.0092573","volume":"9","author":"E Horowitz","year":"2014","unstructured":"Horowitz E, et al. Off-label use of sodium valproate for schizophrenia. PLoS One. 2014;9(3):e92573.","journal-title":"PLoS One"},{"issue":"4","key":"694_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1023\/A:1022130130855","volume":"69","author":"L Citrome","year":"1998","unstructured":"Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q. 1998;69(4):283\u2013300.","journal-title":"Psychiatr Q"},{"issue":"9799","key":"694_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306\u201315.","journal-title":"Lancet"},{"issue":"2","key":"694_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0033291714001305","volume":"45","author":"A Yildiz","year":"2015","unstructured":"Yildiz A, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45(2):299\u2013317.","journal-title":"Psychol Med"},{"issue":"5","key":"694_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bjp.bp.112.117556","volume":"202","author":"KM Abel","year":"2013","unstructured":"Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry. 2013;202(5):321\u20133.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"694_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/schbul\/sbn107","volume":"36","author":"S Gentile","year":"2008","unstructured":"Gentile S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2008;36(3):518\u201344.","journal-title":"Schizophr Bull"},{"issue":"5","key":"694_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","volume":"125","author":"CG Coughlin","year":"2015","unstructured":"Coughlin CG, et al. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224\u20135.","journal-title":"Obstet Gynecol"},{"key":"694_CR32","doi-asserted-by":"publisher","first-page":"h2298","DOI":"10.1136\/bmj.h2298","volume":"350","author":"SN Vigod","year":"2015","unstructured":"Vigod SN, et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298.","journal-title":"BMJ"},{"issue":"3","key":"694_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2009.11.008","volume":"124","author":"DJ Bond","year":"2010","unstructured":"Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010;124(3):228\u201334.","journal-title":"J Affect Disord"},{"issue":"6","key":"694_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/acps.12343","volume":"130","author":"D Taylor","year":"2014","unstructured":"Taylor D, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130(6):452\u201369.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"694_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"G Goodwin","year":"2016","unstructured":"Goodwin G, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495\u2013553.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"694_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"694_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10673220903129814","volume":"17","author":"DV Vigo","year":"2009","unstructured":"Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harvard Rev Psychiatry. 2009;17(4):231\u201341.","journal-title":"Harvard Rev Psychiatry"},{"issue":"5","key":"694_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459\u2013525.","journal-title":"J Psychopharmacol"},{"key":"694_CR39","first-page":"CD00319","volume":"10","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;10:CD00319.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"694_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2215-0366(14)70314-1","volume":"1","author":"T Miura","year":"2014","unstructured":"Miura T, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"694_CR41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40263-017-0452-x","volume":"31","author":"SC Jones","year":"2017","unstructured":"Jones SC, Jones I. Pharmacological management of bipolar disorder in pregnancy. CNS Drugs. 2017;31(9):737\u201345.","journal-title":"CNS Drugs"},{"issue":"7880","key":"694_CR42","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0140-6736(74)91918-7","volume":"304","author":"J Nora","year":"1974","unstructured":"Nora J, Nora A, Toews W. Lithium, Ebstein\u2019s anomaly, and other congenital heart defects. Lancet. 1974;304(7880):594\u20135.","journal-title":"Lancet"},{"issue":"5","key":"694_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1176\/ajp.132.5.529","volume":"132","author":"MR Weinstein","year":"1975","unstructured":"Weinstein MR, Goldfield MD. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry. 1975;132(5):529\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9817","key":"694_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","volume":"379","author":"RF McKnight","year":"2012","unstructured":"McKnight RF, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721\u20138.","journal-title":"Lancet"},{"issue":"6","key":"694_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.euroneuro.2019.04.003","volume":"29","author":"L Wing\u00e5rd","year":"2019","unstructured":"Wing\u00e5rd L, et al. Monotherapy vs combination therapy for post mania maintenance treatment: a population based cohort study. Eur Neuropsychopharmacol. 2019;29(6):691\u2013700.","journal-title":"Eur Neuropsychopharmacol"},{"key":"694_CR46","first-page":"CD004028","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, et al. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016;11:CD004028.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"694_CR47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0004867418772351","volume":"52","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751\u201367.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"694_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","volume":"23","author":"NA Aliyev","year":"2008","unstructured":"Aliyev NA, Aliyev AN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry. 2008;23(2):109\u201314.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"694_CR49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403\u201339.","journal-title":"J Psychopharmacol"},{"issue":"25","key":"694_CR50","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa1312828","volume":"370","author":"KF Huybrechts","year":"2014","unstructured":"Huybrechts KF, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397\u2013407.","journal-title":"N Engl J Med"},{"key":"694_CR51","doi-asserted-by":"publisher","first-page":"f6932","DOI":"10.1136\/bmj.f6932","volume":"348","author":"S Grigoriadis","year":"2014","unstructured":"Grigoriadis S, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.","journal-title":"BMJ"},{"issue":"21","key":"694_CR52","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1001\/jama.2015.5605","volume":"313","author":"KF Huybrechts","year":"2015","unstructured":"Huybrechts KF, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142\u201351.","journal-title":"JAMA"},{"key":"694_CR53","first-page":"CD003499","volume":"2","author":"N Huband","year":"2010","unstructured":"Huband N, et al. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev. 2010;2:CD003499.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"694_CR54","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.euroneuro.2019.09.007","volume":"29","author":"G Anmella","year":"2019","unstructured":"Anmella G, et al. Expert advice on the management of valproate in women with bipolar disorder at childbearing age. Eur Neuropsychopharmacol. 2019;29(11):1199\u2013212.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"694_CR55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00737-018-0851-0","volume":"21","author":"HB Ward","year":"2018","unstructured":"Ward HB, et al. Recommendations for the use of ECT in pregnancy: literature review and proposed clinical protocol. Arch Womens Ment Health. 2018;21(6):715\u201322.","journal-title":"Arch Womens Ment Health"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00694-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00694-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00694-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:51:56Z","timestamp":1607993516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00694-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00694-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"16 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"David S. Baldwin is the Clinical Advisor to the National Clinical Audit of Anxiety and Depression and the Chair of the Psychopharmacology Committee of the Royal College of Psychiatrists, and a Medical Patron of Anxiety UK. Hugo J.F. Amaro has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}